Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing
Molecular Genetics & Genomic Medicine · 2024
DOI: 10.1002/mgg3.2508 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Genetics & Genomic Medicine, 2024. Verfasst von Magan Trottier und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA. Hauptthemen laut MEDLINE: Genetic Counseling, Genetic Testing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Breast Cancer Research Foundation, National Cancer Institute.
Abstract (Originalsprache)
Background
Consumer genomic testing (CGT), including direct‐to‐consumer and consumer‐initiated testing, is increasingly widespread yet has limited regulatory oversight. To assess the current state, we surveyed genetics healthcare providers' experiences with CGT.
Methods
A retrospective survey about experiences counseling on CGT results was completed by 139 respondents recruited from the National Society of Genetic Counselors, Clinical Cancer Genomics Community of Practice, and genetics professional societies.
Results
Among respondents, 41% disagreed with the statement that potential benefits of CGT outweigh harms, 21% agreed, and 38% were undecided. A total of 94% encountered ≥1 challenge counseling CGT patients, including adverse psychosocial events (76%), incorrect variant interpretation (68%), and unconfirmed results (69%); unconfirmed results were more common among oncology providers ( p = 0.03). Providers reporting higher total challenge scores ( p = 0.004) or more psychosocial or interpretation challenges ( p ≤ 0.01) were more likely to indicate CGT harms outweigh benefits. Those with higher CGT clinical volume were more likely to indicate benefits outweigh harms ( p = 0.003). Additional CGT challenges included patient understanding and communication of results, false negatives, incorrect testing/care, and financial costs; seven respondents (6%) documented positive outcomes.
Conclusion
Providers counseling CGT patients encounter psychosocial and medical challenges. Collaborations between regulators, CGT laboratories, providers, and consumers may help mitigate risks.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
- Department of Psychiatry & Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
- Division of Clinical Cancer Genomics, City of Hope Comprehensive Cancer Center, Duarte, Los Angeles, USA.
- Weill Cornell Medical College, New York City, New York, USA.
ORCID-Profile: Jada G Hamilton
Förderung
- NCI NIH HHS
- Breast Cancer Research Foundation
- National Cancer Institute
Zitieren
APA
Trottier, M., Green, D., Ovadia, H., Catchings, A., Gruberg, J., Groner, V., Fanjoy, C., Dandiker, S., Blazer, K., Hamilton, J. G., & Offit, K. (2024). Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing. Molecular Genetics & Genomic Medicine. https://doi.org/10.1002/mgg3.2508
Vancouver
Trottier M, Green D, Ovadia H, Catchings A, Gruberg J, Groner V, et al. Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing. Molecular Genetics & Genomic Medicine. 2024. doi:10.1002/mgg3.2508
BibTeX
@article{Trottier2024,
author = {Trottier, Magan and Green, Dina and Ovadia, Hannah and Catchings, Amanda and Gruberg, Julia and Groner, Victoria and Fanjoy, Catherine and Dandiker, Sita and Blazer, Kathleen and Hamilton, Jada G and Offit, Kenneth},
title = {Genetics healthcare providers' experiences counseling patients with results from consumer genomic testing},
journal = {Molecular Genetics & Genomic Medicine},
year = {2024},
doi = {10.1002/mgg3.2508}
}
EUVIMED